Friday, 16 October 2026European Markets

TEKNA HOLDING Stock Went Up By Over 15% So Far On Wednesday

Loading stream...

Tekna Holding, a notable developer and manufacturer of micro- and nano-powders, has reportedly seen significant growth on the Oslo Bors Benchmark Index_GI. Despite an overall decrease in the index after five days of profit, Tekna Holding's surge only grew stronger, marking four consecutive days of gains by Wednesday afternoon.

Tekna Holding's Closing Price and 52-Week High

Surprisingly, even with its impressive surge, upon closing on its last trading day, Tekna Holding stood at 8.00 Kroner. This is considerably below its notable 52-week high of 20.00 Kroner.

Reported Trading Volume and Stock Price Increase

The substantial increase in Tekna Holding's stock price might be partially due to its reported trading volume, which soared above average. With a reported trading volume of over 85088 shares, it was more than 33.57% above its average trading volume of 63700 shares per day.

EPS and Revenue Growth

Despite having a trailing 12-month earnings per share (EPS) of negative 1.2 kroner, indicating losses, analysts may still see potential growth in Tekna. Interestingly, its year-on-year quarterly revenue growth soared by 42.2%, reaching a whopping 29.69M kroner during the past twelve months. Additionally, Tekna Holding's stock price outshines both its 50-day moving average of 7.14 kroner and 200-day moving average of 6.90 kroner, indicating a positive market sentiment.

Return on Equity and Upward Trajectory

Investors ought to consider Tekna Holding's negative return on equity of -32.23% over the trailing twelve months when evaluating its stock’s upward trajectory. This suggests inefficient utilization of investors' resources during this period. Despite appearing to be on an upswing, Tekna Holding's fundamentals certainly warrant a careful examination.

More news about TEKNA HOLDING (TEKNA.OL).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com